Envarsus: first tablet presentation of tacrolimus

Chiesi has launched Envarsus, the first prolonged-release tablet formulation of tacrolimus. The once-daily tablets are available in 750 microgram, 1mg and 4mg strengths.

Like other oral tacrolimus products, Envarsus should be prescribed by brand name.
Like other oral tacrolimus products, Envarsus should be prescribed by brand name.

Further information
View Envarsus drug record
Manufacturer: Chiesi

Envarsus is licensed for the prevention of transplant rejection in kidney or liver allograft recipients and the treatment of allograft rejection resistant to other immunosuppressants.

Different formulations of tacrolimus are not interchangeable without careful monitoring. Healthcare professionals should be aware of the different bioavailabilities of the available oral formulations and take care to prescribe and dispense the correct product.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from intelog

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

Cases of necrotising fasciitis of the genitalia or...

New advice for carbimazole over malformation and pancreatitis risks

New advice for carbimazole over malformation and pancreatitis risks

Reports of congenital malformations and acute pancreatitis...

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Antibiotic Treatments in Adults, Summary of Regimens

Antibiotic Treatments in Adults, Summary of Regimens

Dose regimens for common bacterial infections.